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The genome sequence of Yaba-like disease virus (YLDV), an unclassified member of the yatapoxvirus genus, has been
determined. Excluding the terminal hairpin loops, the YLDV genome is 144,575 bp in length and contains inverted terminal
repeats (ITRs) of 1883 bp. Within 20 nucleotides of the termini, there is a sequence that is conserved in other poxviruses and
is required for the resolution of concatemeric replicative DNA intermediates. The nucleotide composition of the genome is
73% A1T, but the ITRs are only 63% A1T. The genome contains 151 tightly packed open reading frames (ORFs) that either
are $180 nucleotides in length or are conserved in other poxviruses. ORFs within 23 kb of each end are transcribed toward
the termini, whereas ORFs within the central region of the genome are encoded on either DNA strand. In the central region
ORFs have a conserved position, orientation, and sequence compared with vaccinia virus ORFs and encode many enzymes,
transcription factors, or structural proteins. In contrast, ORFs near the termini are more divergent and in seven cases are
without counterparts in other poxviruses. The YLDV genome encodes several predicted immunomodulators; examples
include two proteins with similarity to CC chemokine receptors and predicted secreted proteins with similarity to MHC class
I antigen, OX-2, interleukin-10/mda-7, poxvirus growth factor, serpins, and a type I interferon-binding protein. Phylogenic
analyses indicated that YLDV is very closely related to yaba monkey tumor virus, but outside the yatapoxvirus genus YLDV
is more closely related to swinepox virus and leporipoxviruses than to other chordopoxvirus genera. © 2001 Academic Press
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Poxviruses are large DNA viruses that infect insects
(entomopoxviruses) or vertebrates (chordopoxviruses)
(Fenner, 1996). The chordopoxvirus group is divided into
eight genera, orthopox, parapox, capripox, leporipox, sui-
pox, avipox, molluscipox, and yatapox, of which the or-
thopoxviruses have been the most important for humans
and include variola virus (VAR) (the cause of smallpox),
vaccinia virus (VV) (the vaccine used to eradicate small-
pox), cowpox virus (CPV), and monkeypox virus. All pox-
viruses replicate in the cell cytoplasm and encode their
own enzymes for transcription and DNA replication
(Moss, 1996).
The nucleotide sequence of several poxviruses has
been determined. These include VV strains Copenhagen
(CPN) (Goebel et al., 1990), modified virus Ankara
(Antoine et al., 1998), and the majority of Western Re-
serve (WR) (Smith et al., 1991, and references therein),
VAR strains Bangladesh-1975 (VAR-BSH) (Massung et al.,
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1701994), India-1968 (Shchelkunov et al., 1995), and Garcia-
1966 (Shchelkunov et al., 2000), molluscum contagiosum
virus (MCV) (Senkevich et al., 1997), Melanoplus sangui-
nipes entomopoxvirus (MSV) (Afonso et al., 1999), Shope
fibroma virus (SFV) (Willer et al., 1999), myxoma virus
(MYX) (Cameron et al., 1999), fowlpox virus (FPV) (Afonso
et al., 2000), and camelpox virus (CMPV) (Gubser and
Smith, submitted for publication).
The yatapoxvirus genus contains three members: ta-
napox virus (TPV), yaba monkey tumor virus (YMTV), and
yaba-like disease virus (YLDV) (Knight et al., 1989). All
these viruses are morphologically similar to orthopoxvi-
ruses but are antigenically distinct from members of this
and other poxvirus genera and hence cannot be neutral-
ized by polyclonal antisera raised against VV, MCV, or orf
virus (OV), a parapoxvirus (Downie et al., 1971). Yatapox-
viruses have a narrow host range and infect monkeys but
can also be transmitted to humans where they may
cause a mild febrile illness lasting a few days with one or
two lesions (deHarven and Yohn, 1966; Espan˜a et al.,
1971). The progression of yatapoxvirus-induced pathol-
ogy is considerably slower than that for orthopoxviruses.
TPV was isolated from the skin lesions of patients during
outbreaks in the Tana River valley in Kenya in 1957 to
1962 (Downie et al., 1971). YMTV was isolated from a
colony of rhesus monkeys near Lagos, West Africa in
1958 (Bearcroft and Jamieson, 1958) and can produce
tumor-like lesions with masses of mesodermal tissue
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171GENOME SEQUENCE OF YLDV(Niven et al., 1961). YLDV was isolated in 1965–1966 from
onkeys and animal handlers in primate centers in the
nited States (Casey et al., 1967; Hall and McNulty, 1967;
icholas and McNulty, 1968; Espan˜a, 1971). The YLDV-
nduced lesions in monkeys and clinical signs in humans
re similar to TPV and these viruses are biologically
ndistinguishable (McNulty et al., 1968; Downie and Es-
pan˜a, 1972). Serological cross-reactivity between yata-
poxviruses has been reported (Nicholas and McNulty,
1968; Kupper et al., 1970).
Yatapoxviruses have a 145-kb, linear, double-stranded
(ds) DNA genome with covalently closed hairpin ends
and variations have been noted in the restriction patterns
of the different viruses (Knight et al., 1989). Cross-hybrid-
ization experiments indicated some sequence conserva-
tion between YMTV and monkeypox virus (Rouhandeh et
al., 1982), but until recently very little sequence data were
available for the yatapoxviruses. Part of the YMTV ge-
nome was deposited in a public database (Amano et al.,
1995, 2000a, b; Amano and Miyamura, 2000) and small
fragments of the TPV genome have been sequenced
(Neering and Essani, 1999).
To gain an increased understanding of the yatapoxvi-
ruses and their evolutionary relationships with other pox-
viruses, we have determined the sequence of YLDV with
the exception of the terminal hairpins. The genome is
144,575 bp and contains 151 open reading frames
(ORFs). The ORFs within the central 100 kb of the ge-
nome show considerable similarity to corresponding
ORFs in VV in their deduced amino acid sequence, po-
sition, and direction of transcription. Several potential
immunomodulators are identified and the evolutionary
relationship of YLDV with other poxviruses is discussed.
RESULTS AND DISCUSSION
Genome structure of YLDV
A total of 1,098,770 nucleotides of YLDV DNA were
assembled into a contiguous sequence of 144,575 bp.
Ninety-seven point nine percent of these data were ob-
tained from sequencing random clones and the remain-
ing 2.1% were obtained from direct sequencing of either
genomic DNA or 10-kb clones using specific oligonucle-
otide primers. The average character density was 7.6 per
nucleotide and 99.0% of the sequence was obtained from
both DNA strands. Every position was sequenced at
least twice. The genome was composed of 73% A1T,
making YLDV the most A1T-rich chordopoxvirus to have
been sequenced. Only the genome of the entomopoxvi-
rus MSV has a higher A1T content (81%) (Afonso et al.,
1999).
The sequence obtained did not include the terminal
hairpins because, as expected, these were not cloned
into either library and attempts to sequence these di-
rectly using virus DNA as template and specific oligonu-
cleotides were unsuccessful. Therefore, the exact length
t
tof the virus genome is unknown. However, several lines
of evidence indicate that the sequence obtained came
very close to the terminal hairpins. First, the length ob-
tained (144,575 bp) was very similar to the total length of
the YLDV genome (146.5 bp) estimated from restriction
enzyme digestion and gel electrophoresis (Knight et al.,
1989). Second, the size of the terminal PstI restriction
fragments described by others (Knight et al., 1989) and
observed experimentally by us was indistinguishable
from the length predicted by computer from the se-
quence generated here. Third, and most compelling, a
sequence motif was identified within 20 nucleotides of
each terminus that is conserved perfectly with se-
quences found very close to the terminal hairpins of
other poxviruses and known to be required for the res-
olution of concatemeric DNA replicative intermediates
(Merchlinsky and Moss, 1989) (Fig. 1). In VV strains WR
(Baroudy et al., 1982) and CPN (Goebel et al., 1990) and
AR-BSH (Massung et al., 1994) this conserved se-
uence is located within 60 bp of the terminal hairpins.
he motif is also present in FPV (Afonso et al., 2000), SFV
nd MYX (Cameron et al., 1999; Willer et al., 1999), and
CV (Senkevich et al., 1996). This observation extended
FIG. 1. Schematic representation of the YLDV ITRs. Each ITR is
shown together with the positions of the terminal ORFs, the concate-
mer resolution sequence, and the presumed terminal hairpin. Shown
beneath the right ITR is the concatemeric resolution sequence from VV,
MCV, FPV, SFV, and YLDV. Nucleotides conserved in at least four of five
sequences are boxed.he number of chordopoxvirus genera known to contain
his sequence and suggested that the mechanism of
t indica
nds of
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other poxviruses.
The YLDV genome contains inverted terminal repeats
(ITRs) of 1883 bp (Fig. 1). This compares with ITRs of 725
bp in VAR-BSH (Massung et al., 1994), 12 kb in VV strain
CPN (Goebel et al., 1990), and 50 kb in some mutants of
CPV (Pickup et al., 1984). The YLDV ITR lacks repeated
sequences such as the multiple copies of 50 to 70
nucleotides in the ITRs of several orthopoxviruses (Ba-
FIG. 2. YLDV genetic map. Each ORF is represented by an arrow tha
proteins with similar functions. ITRs are shown as black bars at the eroudy and Moss, 1982; Goebel et al., 1990; Massung et
al., 1994). In these viruses these repeated sequenceswere proposed to contribute to genome length hetero-
geneity. Repeated sequences are also present within the
MSV ITR (Afonso et al., 1999). The YLDV ITR is predicted
to encode protein to within 758 nucleotides of the termi-
nus of the determined sequence, whereas some other
poxviruses, such as VV, have longer noncoding regions
in the ITR (Goebel et al., 1990). A notable feature of the
YLDV genome was that the ITR had a lower A1T content
(63%) than the genome as a whole (73%). The signifi-
tes the approximate size and direction of transcription. Colors indicate
the genome. Each full-length line shows 20 kb.cance of this is unknown. Similarly, the leporipoxviruses
MYX (Cameron et al., 1999) and SFV (Willer et al., 1999)
TABLE 1
Properties of YLDV ORFs and the Encoded Proteins
ORFa Start/stop AAb kDac IPd TOE Features, putative function Identity/similarity Reference
1L 1,756–755 333 38.5 5.5 E VV C10L (330 aa) 27%/49% in 333 Goebel et al. (1990)
2L 2,885–1,869 338 38.8 5.4 ? Soluble MHC-I protein (?), 1 Ig domain, SP
SPV C1L/murine IgE C chain (340 aa) 38%/53% in 336 Massung et al. (1993)
Chicken MHC-I glycoprotein (355 aa) 22%/44% in 341 Hunt and Fulton (1998)
3L 3,600–2,932 222 26.6 9.1 L SPV C5L (236 aa) 43%/65% in 215 Massung et al. (1993)
VV K7R (149 aa) 24%/53% in 149 Goebel et al. (1990)
4L 4,346–3,630 238 28.5 6.3 L VV N2L (175 aa)/a-amanitin sensitivity 25%/60% in 174 Tamin et al. (1991)
SPV C5L (236 aa) 32%/55% in 222 Massung et al. (1993)
5L 4,856–4,386 156 18.3 8.0 L 2 TMs
SPV C7L (155 aa) 32%/53% in 155 Massung et al. (1993)
6L 5,369–4,920 149 17.2 6.0 E VV B15R (149 aa) 40%/61% in 139 Goebel et al. (1990)
CPV B13R (149 aa) 41%/62% in 139 Shchelkunov et al. (1998)
7L 6,488–5,433 351 41 9.5 L CC chemokine receptor, 7 TMs
Macaca mulatta chemokine receptor 57%/77% in 309 Margulies et al. (1999)
Human CC chemokine receptor type 8 (355 aa) 53%/73% in 343 Tiffany et al. (1997)
CAPV Q2/3L/G-protein-coupled receptor (381 aa) 39%/65% in 229 Cao et al. (1995)
SPV K2R/G-protein-coupled receptor (370 aa) 35%/61% in 368 Massung et al. (1993)
8L 7,146–6,505 213 25.1 5.2 E 4 ankyrin domains
CAPV Q2/2L (202 aa) 40%/61% in 197 Cao et al. (1995)
VV M1L (421 aa, WR)/ankyrin repeat region 28%/53% in 260 Tamin et al. (1988)
9L 7,863–7,183 226 25.6 7.8 ? SP, VV M2L (220 aa) 28%/50% in 219 Goebel et al. (1990)
10L 9,036–7,885 383 43.6 10.3 L SERP-I, serpin domain, SP
MYX SERP-1 (369 aa) 33%/55% in 355 Upton et al. (1990a)
VV K2L/SPI-3 (369 aa) 29%/52% in 367 Boursnell et al. (1988)
11L 10,961–9,048 637 73.4 9.9 ? 14 ankyrin domains
Human ankyrin (1856 aa) 25%/49% in 726 Forget et al. (1997)
VV B4R (558 aa) 25%/48% in 552 Howard et al. (1991)
12L 11,247–10,981 88 9.8 9.8 E eIF2a mimic/resistance to IFN
SPV C8L (86 aa) 44%/66% in 82 Massung et al. (1993)
VV K3L (88 aa)/eIF2a 37%/55% in 81 Beattie et al. (1991)
13L 12,136–11,279 285 32.7 9.8 L Monoglyceride lipase, zinc finger motif
Mouse monoglyceride lipase (303 aa) 37%/60% in 278 Karlsson et al. (1997)
CPV M5L (276 aa) 38%/51% in 276 Shchelkunov et al. (1998)
14L 12,569–12,159 136 16.1 9.9 ? IL-18-binding protein, SP
SPV C9L (134 aa) 33%/50% in 127 Massung et al. (1993)
MCV MC053L (133 aa) 27%/38% in 92 Senkevich et al. (1997)
MCV MC054L (235 aa) 24%/34% in 122 Senkevich et al. (1997)
Human IL-18-binding protein (192 aa) 24%/33% in 136 Novick et al. (1999)
Mouse IL-18-binding protein (193 aa) 21%/33% in 136 Novick et al. (1999)
15L 12,830–12,597 77 8.8 8.6 ? Growth factor, EGF domain, SP
MYX growth factor (85 aa) 40%/60% in 80 Upton et al. (1987)
16L 13,360–12,830 176 20.5 7.7 L Virulence factor, 2 TMs
SPV C10L (167 aa) 28%/59% in 166 Massung et al. (1993)
MYX M11L (166 aa)/virulence factor 25%/49% in 161 Graham et al. (1992)
17L 13,836–13,405 143 15.4 8.4 ? dUTPase
SPV dUTPase (142 aa) 64%/77% in 142 Massung et al. (1993)
VV F2L (147 aa)/dUTPase 56%/74% in 140 Broyles (1993)
18L 14,261–13,878 127 15 10.6 ? SPV C12L (75 aa) 32%/54% in 75 Massung et al. (1993)
19L 15,861–14,293 522 60.2 7.1 ? Kelch-like protein
SPV C13L (500 aa) 38%/61% in 494 Massung et al. (1993)
VV C2L (512 aa) 25%/48% in 484 Goebel et al. (1990)
VV A55R (564 aa) 24%/46% in 527 Goebel et al. (1990)
20L 16,863–15,886 325 37.8 5.3 L Ribonucleotide reductase small subunit
VV F4L (319 aa)/ribonucleotide reductase small
subunit
77%/85% in 317 Roseman and Slabaugh (1990)
21L 17,139–16,891 82 9.4 7.5 ? TM
SPV C15L (86 aa) 34%/68% in 86 Massung et al. (1993)
22L 17,495–17,184 103 12.2 5.9 ?
23L 17,712–17,497 71 8.5 10.0 ?
24L 18,732–18,088 214 24.3 8.3 ? TM
VV F9L (212 aa) 52%/76% in 212 Goebel et al. (1990)
SPV C19L (215 aa) 49%/74% in 215 Massung et al. (1993)
25L 20,047–18,710 445 52.9 7.0 L Serine/threonine protein kinase
SPV C20L (440 aa)/possible protein kinase 76%/87% in 440 Massung et al. (1993)
VV F10L (439 aa)/serine/threonine kinase 2 72%/83% in 439 Lin and Broyles (1994)
26L 21,999–20,071 642 73.5 8.9 ? 4 TMs
VV F12L (635 aa) 38%/59% in 630 Goebel et al. (1990)
27L 23,143–22,031 370 41.5 7.2 L EEV protein
MYX MF13 (371 aa)/envelope protein 72%/83% in 367 Jackson and Hall (1998)
VV F13L (372 aa)/37-kDa EEV antigen 58%/74% in 367 Hirt et al. (1986)
28R 23,215–23,436 73 8.8 10.6 ? TM
29L 24,036–23,590 148 17.2 9.7 E TM
VV F15L (158 aa) 57%/74% in 146 Goebel et al. (1990)
30L 24,748–24,101 215 24.8 10.7 ? SP
VV F16L (231 aa) 41%/60% in 224 Goebel et al. (1990)
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31R 24,807–25,124 105 11.8 9.9 L DNA-binding phosphoprotein
MYX MF17 (102 aa) 72%/80% in 100 Jackson and Hall (1998)
VV F17R (101 aa)/DNA-binding 11-kDa phosphoprotein
(VP11)
55%/72% in 101 Kao and Bauer (1987)
32L 26,533–25,121 470 54.2 9.7 L Poly(A) polymerase catalytic subunit
VV E1L (479 aa)/poly(A) polymerase catalytic subunit
(VP55)
66%/81% in 468 Gershon et al. (1991)
33L 28,607–26,550 685 79.8 7.8 L VV E2L (737 aa) 42%/66% in 730 Goebel et al. (1990)
34L 29,224–28,667 185 21.3 9.5 ? dsRNA-binding protein/resistance to IFN
VV E3L (190 aa)/dsRNA-binding protein/resistance to
IFN/host range
38%/55% in 187 Chang et al. (1992, 1995)
OV OV20.0L (183 aa)/resistance to IFN 28%/50% in 183 Haig et al. (1998)
35L 29,833–29,264 189 22 9.2 ? RNA polymerase subunit rpo30/intermediate
transcription factor-1
VV E4L (259 aa)/RNA polymerase 30-kDa
subunit/intermediate transcription factor-1
71%/81% in 186 Ahn et al. (1990a); Rosales et al.
(1994)
36R 29,950–30,996 348 41.2 10.2 ? CMPV E5 (329 aa) 26%/50% in 322 Douglas and Dumbell (1996)
VV E5R (331 aa) 24%/47% in 324 Goebel et al. (1990)
37R 30,997–32,700 567 67.1 7.1 L VV E6R (567 aa) 62%/81% in 567 Goebel et al. (1990)
38R 32,720–33,526 268 31.5 8.9 ? Homeobox domain signature
VV E8R (273 aa) 69%/80% in 263 Goebel et al. (1990)
39L 36,543–33,523 1006 116.9 8.3 ? DNA polymerase
VV E9L (1006 aa)/DNA polymerase 69%/81% in 1005 Earl et al. (1986)
FPV DNA polymerase (988 aa) 51%/68% in 1006 Binns et al. (1987)
40R 36,577–36,861 94 10.9 8.8 ? TM, SP
VV E10R (95 aa) 66%/78% in 95 Goebel et al. (1990)
41L 37,247–36,858 129 15.2 5.3 L TM
VV E11L (129 aa) 43%/70% in 129 Goebel et al. (1990)
42L 39,273–37,234 679 78 10.1 E VV O1L (666 aa) 39%/63% in 666 Goebel et al. (1990)
43L 40,377–39,442 311 36 9.0 L DNA-binding core protein
VV I1L (312 aa)/DNA-binding core protein 69%/83% in 311 Klemperer et al. (1997)
44L 40,605–40,378 75 8.5 4.5 L TM
VV I2L (73 aa) 47%/74% in 72 Goebel et al. (1990)
45L 41,406–40,606 266 29.7 6.6 E ssDNA-binding phosphoprotein
VV I3L (269 aa)/ssDNA-binding phosphoprotein 54%/71% in 269 Davis and Mathews (1993);
Rochester and Traktman
(1998)
46L 41,710–41,471 79 8.5 10.6 L Structural protein, TM, SP
VV I5L (79 aa)/VP13 43%/72% in 75 Takahashi et al. (1994)
47L 42,888–41,728 386 44.9 8.8 L VV I6L (382 aa) 53%/74% in 386 Schmitt and Stunnenberg (1988)
48L 44,174–42,885 429 50.1 8.4 L Topoisomerase II
VV I7L (423 aa)/topoisomerase II 69%/85% in 429 Kane and Shuman (1993)
49R 44,180–46,213 677 78.6 10.1 L RNA and DNA helicase
VV I8R (676 aa)/RNA & DNA helicase 58%/74% in 672 Shuman (1992); Bayliss and
Smith (1996)
50L 47,982–46,210 590 68.6 8.2 L Protease
VV G1L (591 aa)/protease 55%/76% in 591 Whitehead and Hruby (1994)
51L 48,314–47,979 111 13 9.6 L SP
VV G3L (111 aa) 45%/63% in 111 Goebel et al. (1990)
52R 48,308–48,976 222 25.5 10.3 I Late transcription elongation factor, SP
VV G2R (220 aa)/late transcription elongation factor 49%/72% in 220 Condit et al. (1996)
53L 49,320–48,943 125 14.5 5.1 L Glutaredoxin 2
VV G4L (124 aa)/glutaredoxin 2 43%/65% in 124 Gvakharia et al. (1996)
54R 49,323–50,642 439 51.1 8.7 ? VV G5R (434 aa) 45%/65% in 433 Goebel et al. (1990)
55R 50,645–50,836 63 7.3 8.2 ? RNA polymerase subunit rpo7
VV G5.5R (63 aa)/RNA polymerase 7-kDa subunit 79%/88% in 63 Amegadzie et al. (1992)
56R 50,836–51,378 180 20.5 8.9 ? TM
VV G6R (165 aa) 49%/71% in 159 Goebel et al. (1990)
57L 52,471–51,347 374 42.6 8.4 L IMV structural protein
VV G7L (371 aa)/structural protein, VP16 54%/72% in 367 Takahashi et al. (1994)
58R 52,501–53,283 260 29.8 8.0 I/L Late transcription factor
VV G8R (260 aa)/VLTF-1 83%/94% in 260 Keck et al. (1990)
59R 53,296–54,300 334 38.4 7.1 L Myristylprotein, TM
VV G9R (340 aa)/myristylprotein 51%/69% in 340 Martin et al. (1997)
60R 54,301–55,044 247 26.8 6.5 L Myristylated IMV protein, TM
VV L1R (250 aa)/25-kDa myristylprotein 67%/80% in 247 Franke et al. (1990)
61R 55,063–55,338 91 11 8.4 L 2 TMs
VV L2R (87 aa) 28%/70% in 85 Goebel et al. (1990)
62L 56,264–55,314 316 36.9 8.3 L VV L3L (350 aa) 51%/72% in 319 Goebel et al. (1990)
63R 56,289–57,038 249 28.6 5.9 L IMV structural protein
VV L4R (251 aa)/IMV structural protein VP8, DNA/RNA-
binding protein
60%/82% in 247 Yang and Bauer (1988); Bayliss
and Smith (1997)
64R 57,054–57,440 128 14.8 9.7 L TM
VV L5R (128 aa) 46%/68% in 128 Goebel et al. (1990)
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TABLE 1—Continued
ORFa Start/stop AAb kDac IPd TOE Features, putative function Identity/similarity Reference
65R 57,394–57,873 159 18.6 5.4 ? CAPV F7 (147 aa) 67%/77% in 147 Gershon and Black (1989)
MYX MF7 (148 aa) 59%/70% in 148 Jackson and Bults (1992)
VV J1R (153 aa) 49%/66% in 153 Goebel et al. (1990)
66R 57,870–58,421 183 20.5 8.4 ? Thymidine kinase
YMTV thymidine kinase (181 aa) 82%/90% in 183 Amano et al. (1995)
VV J2R (177 aa)/thymidine kinase 68%/77% in 175 Hruby et al. (1983); Weir and
Moss (1983)
67R 58,469–59,005 178 21 4.5 E Host range protein
SPV SWF8A (185 aa) 45%/68% in 179 Schnitzlein and Tripathy (1991)
VV C7L (150 aa)/host range protein 35%/66% in 150 Perkus et al. (1990)
68R 58,983–60,074 363 42.8 10.4 ? Poly(A) polymerase regulatory subunit
MYX F9 (338 aa) 73%/85% in 333 Jackson and Bults (1990)
VV J3R (333 aa)/poly(A) polymerase regulatory subunit
(VP39)
71%/85% in 333 Gershon and Moss (1993)
69R 59,989–60,546 185 21.1 6.8 ? RNA polymerase subunit rpo22
VV J4R (185 aa)/RNA polymerase 22-kDa subunit 74%/88% in 185 Broyles and Moss (1986)
70L 60,936–60,523 137 15.9 7.8 L 1 TM
VV J5L (133 aa) 62%/78% in 130 Goebel et al. (1990)
71R 61,027–64,884 1285 147.6 8.8 E RNA polymerase subunit rpo147
VV J6R (1286 aa)/RNA polymerase 147-kDa subunit 80%/89% in 1286 Broyles and Moss (1986)
RNA polymerase subunit family ,80%
72L 65,396–64,881 171 19.9 10.1 L Tyrosine/serine phosphatase
VV H1L (171 aa)/tyrosine/serine phosphatase 64%/83% in 171 Guan et al. (1991)
73R 65,412–65,984 190 21.9 9.3 ? TM
VV H2R (189 aa) 62%/78% in 188 Goebel et al. (1990)
74L 66,958–65,987 323 37.3 6.8 L Immunodominant envelope protein, TM
VV H3L (324 aa)/immunodominant envelope protein
p35
35%/64% in 320 Chertov et al. (1991)
75L 69,355–66,959 798 94.7 7.7 L RNA polymerase-associated transcription specificity
factor (RAP) 94
VV H4L (795 aa)/RAP 94 69%/84% in 798 Ahn and Moss (1992); Kane and
Shuman (1992)
76R 69,514–70,056 180 20.2 9.0 I Late transcription factor VLTF-4
VV H5R (203 aa)/late transcription factor-4 46%/61% in 203 Kovacs and Moss (1996)
77R 70,069–71,016 315 36.9 10.5 I/L DNA topoisomerase I
SFV DNA topoisomerase I (314 aa) 64%/81% in 314 Upton et al. (1990b)
VV H6R (314 aa)/DNA topoisomerase I 63%/77% in 313 Shuman and Moss (1987)
78R 71,032–71,478 148 17 9.9 L VV H7R (146 aa) 39%/62% in 143 Goebel et al. (1990)
79R 71,516–74,038 840 97.9 9.0 L mRNA capping enzyme large subunit
SFV mRNA capping enzyme large subunit (836 aa) 69%/84% in 834 Upton et al. (1991)
VV D1R (844 aa)/mRNA capping enzyme large subunit 66%/81% in 844 Morgan et al. (1984)
80L 74,461–74,000 154 18.1 10.1 L Structural protein
VV D2L (146 aa)/structural protein 52%/73% in 139 Dyster and Niles (1991)
81R 74,460–75,197 245 28.4 7.5 ? Structural protein
VV D3R (237 aa)/structural protein 39%/58% in 245 Dyster and Niles (1991)
82R 75,194–75,850 218 25.1 8.5 L Uracil-DNA glycosylase
SFV uracil-DNA glycosylase (218 aa) 72%/87% in 218 Upton et al. (1993)
VV D4R (218 aa)/uracil-DNA glycosylase 69%/88% in 218 Stuart et al. (1993)
83R 75,956–78,316 786 90.1 7.8 ? NTPase, ATP/GTP-binding site motif A (P-loop)
VV D5R (785 aa)/NTPase 69%/82% in 785 Evans et al. (1995)
84R 78,313–80,220 635 73.1 9.1 L Early transcription factor
SFV early transcription factor 70-kDa subunit (635 aa) 86%/93% in 635 Strayer et al. (1991)
VV D6R (637 aa)/early transcription factor 70-kDa
subunit
80%/90% in 637 Broyles and Fesler (1990);
Gershon and Moss (1990)
85R 80,253–80,735 160 17.9 5.8 L RNA polymerase subunit rpo18
VV D7R (161 aa)/RNA polymerase 18-kDa subunit 71%/84% in 160 Ahn et al. (1990b); Quick and
Broyles (1990)
86R 80,780–81,418 212 24.7 8.6 ? mutT protein, mutT domain signature
VV D9R (213 aa)/mutT 60%/76% in 206 Koonin (1993)
87R 81,415–82,182 255 29.9 10.2 L Negative regulator of gene expression, mutT domain
signature
SFV D10R (260 aa)/mutT 60%/75% in 250 Strayer et al. (1991)
VV D10R (248 aa)/negative regulator of gene
expression
51%/69% in 248 Shors et al. (1999)
88L 84,070–82,175 631 72.8 10.0 L RNA polymerase elongation factor
VV D11L (631 aa)/NPH-I 70%/83% in 631 Christen et al. (1998); Deng and
Shuman (1998)
89L 84,965–84,102 287 33.4 8.1 I/L mRNA capping enzyme small subunit
SPV mRNA capping enzyme small subunit (287 aa) 82%/93% in 287 Massung et al. (1993)
VV D12L (287 aa)/mRNA capping enzyme small
subunit
74%/89% in 287 Niles et al. (1989)
90L 86,652–84,994 552 62.3 6.5 L Rifampicin resistance
SPV rifampicin resistance protein (551 aa) 78%/89% in 550 Massung et al. (1993)
VV D13L (551 aa)/rifampicin resistance 73%/84% in 551 Tartaglia and Paoletti (1985)
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91L 87,128–86,676 150 17 9.0 I/L Late gene transcription factor
VV A1L (150 aa)/VLTF-2 64%/85% in 150 Keck et al. (1993)
92L 87,826–87,152 224 26.1 8.6 I/L Late gene transcription factor
VV A2L (224 aa)/VLTF-3 84%/95% in 224 Hubbs and Wright (1996)
93L 88,050–87,823 75 9.1 10.2 L VV WR hypothetical 8.9-kDa protein (76 aa) 56%/69% in 76 Weinrich and Hruby (1986)
94L 90,033–88,060 657 75.4 6.9 L Core structural protein
VV A3L (644 aa)/core structural protein P4b 65%/81% in 657 Rosel and Moss (1985)
95L 90,548–90,090 152 17.5 5.1 ? Membrane-associated protein
VV A4L (281 aa)/membrane-associated protein 30%/65% in 76 Cudmore et al. (1996)
96R 90,588–91,094 168 19.2 4.2 ? RNA polymerase subunit rpo19
VV A5R (164 aa)/RNA polymerase 19-kDa subunit 63%/80% in 168 Ahn et al. (1992)
97L 92,206–91,091 371 43.2 8.8 I/L VV A6L (372 aa) 58%/77% in 368 Goebel et al. (1990)
98L 94,365–92,230 711 81.9 8.5 L Early transcription factor 82-kDa subunit
VV A7L (710 aa)/early transcription factor 82-kDa
subunit
71%/85% in 711 Gershon and Moss (1990)
99R 94,418–95,290 290 33.9 9.2 L Intermediate gene transcription factor subunit
VV A8R (288 aa)/VITF-3 61%/78% in 288 Sanz and Moss (1999)
100L 95,526–95,287 79 9 8.7 L TM, SP
VV A9L (99 aa) 73%/86% in 90 Goebel et al. (1990)
101L 98,235–95,527 902 103 6.4 L Core structural protein P4a
VV A10L (891 aa)/core structural protein P4a 54%/72% in 902 Van Meir and Wittek (1988)
102R 98,250–99,185 311 34.9 5.6 L VV A11R (318 aa) 57%/79% in 318 Goebel et al. (1990)
103L 99,707–99,195 170 18.3 10.4 ? Structural protein
VV A12L (192 aa)/structural protein 54%/70% in 191 Takahashi et al. (1994)
104L 99,956–99,750 68 7.7 9.2 ? IMV membrane protein, TM
VV A13L (70 aa)/IMV membrane protein P8 31%/55% in 70 Jensen et al. (1996)
105L 100,285–100,004 93 10.1 8.7 ? IMV membrane protein, 2 TMs
VV A14L (90 aa)/IMV membrane protein P16 56%/72% in 90 Jensen et al. (1996)
106L 100,453–100,302 53 6.2 8.4 L IMV membrane protein, SP, TM
VV A14.5L (53 aa)/IMV membrane protein 52%/63% in 51 Betakova et al. (2000)
107L 100,737–100,453 94 10.8 9.3 L VV A15L (94 aa) 52%/68% in 94 Goebel et al. (1990)
108L 101,866–100,721 381 44.6 8.8 L Myristylprotein, TM
VV A16L (378 aa)/myristylprotein 52%/71% in 381 Martin et al. (1997)
109L 102,455–101,880 191 20.9 4.8 L IMV membrane protein, 4 TMs
VV A17L (203 aa)/IMV membrane protein 41%/65% in 197 Rodriguez et al. (1995)
110R 102,470–103,909 479 55.6 10.8 I/L DNA helicase
VV A18R (493 aa)/DNA helicase 56%/71% in 493 Simpson and Condit (1995)
111L 104,114–103,890 74 7.9 9.8 ? VV A19L (77 aa) 63%/79% in 69 Goebel et al. (1990)
112L 104,447–104,115 110 12.7 8.6 L SP
VV A21L (117 aa) 59%/72% in 117 Goebel et al. (1990)
113R 104,446–105,723 425 49 8.9 ? DNA polymerase processivity factor
VV A20R (426 aa)/DNA polymerase processivity factor 47%/67% in 424 McDonald et al. (1997)
114R 105,732–106,205 157 18.5 10.7 L TM
VV A22R (176 aa) 67%/85% in 157 Goebel et al. (1990)
115R 106,227–107,378 383 44.5 10.3 L Intermediate gene transcription factor subunit
VV A23R (382 aa)/VITF-3 61%/77% in 380 Sanz and Moss (1999)
116R 107,380–110,877 1165 133.8 8.1 L RNA polymerase subunit rpo132
CPV RNA polymerase 132-kDa subunit (1164 aa) 82%/91% in 1164 Patel and Pickup (1989)
VV A24R (1164 aa)/RNA polymerase 132-kDa subunit 82%/91% in 1163 Amegadzie et al. (1991)
CAPV RNA polymerase subunit (919 aa) 87%/93% in 919 Gershon et al. (1989)
117L 111,320–110,874 148 17.2 5.0 ? IMV surface protein
CAPV HM2 (148 aa)/putative fusion protein 42%/62% in 146 Gershon et al. (1989)
VV A27L (110 aa)/IMV surface protein 39%/55% in 106 Rodriguez and Smith (1990)
118L 111,740–111,321 139 16.1 6.5 L SP
MYX MA28L (140 aa)/hypothetical 16-kDa protein 63%/80% in 140 Jackson et al. (1996)
CAPV HM3 (140 aa) 62%/81% in 140 Gershon et al. (1989)
VV A28L (146 aa) 58%/73% in 146 Goebel et al. (1990)
119L 112,655–112,753 300 35.1 6.2 ? RNA polymerase subunit rpo35
VV A29L (305 aa)/RNA polymerase 35-kDa subunit 57%/75% in 296 Amegadzie et al. (1991)
120L 112,851–112,624 75 8.6 7.5 ? VV A30L (77 aa, WR) 49%/69% in 75 Amegadzie et al. (1991)
MCV MC136L (67 aa) 48%/69% in 65 Senkevich et al. (1997)
121L 113,814–113,053 253 29.1 9.7 L ATP/GTP-binding site motif A (P-loop)
MCV MC140L (249 aa) 63%/80% in 247 Senkevich et al. (1997)
VV A32L (300 aa)/ATP/GTP-binding motif 60%/74% in 254 Koonin et al. (1993); Cassetti
et al. (1998)
122R 113,926–114,486 186 21 4.7 L EEV glycoprotein, TM
VV A33R (185 aa)/EEV glycoprotein 38%/61% in 178 Roper et al. (1996)
123R 114,509–115,021 170 19.5 10.4 L EEV glycoprotein, 1 TM, C-type lectin domain
VV A34R (168 aa)/EEV glycoprotein 50%/68% in 170 Duncan and Smith (1992)
124R 115,059–115,598 179 20.5 6.5 ? VV A35R (176 aa) 40%/61% in 171 Goebel et al. (1990)
MCV MC145R (233 aa) 26%/53% in 179 Senkevich et al. (1997)
125R 115,634–116,491 285 32.9 8.3 E MCV MC144R (642 aa) 23%/48% in 285 Senkevich et al. (1997)
FPV hypothetical 32.4-kDa protein (283 aa) 26%/48% in 278 Hertig et al. (1997)
126R 116,549–117,220 223 25.9 4.2 ? SP
127R 117,265–118,077 270 31.5 10.1 L VV A37R (263 aa) 25%/53% in 253 Goebel et al. (1990)
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128L 118,890–118,072 272 32.1 10.4 L CD47, 5 TMs, SP
Human CD47 precursor (323 aa) 24%/48% in 311 Campbell et al. (1992)
VV A38L (277 aa, WR)/integral membrane glycoprotein 23%/47% in 276 Parkinson et al. (1995)
129R 118,900–119,316 138 16 7.6 L VV E7R (166 aa)/myristylprotein 26%/48% in 145 Martin et al. (1997)
130L 119,862–119,302 186 21.2 9.1 L SP
131R 119,939–120,145 68 7.6 4.7 ?
132R 120,173–120,421 82 9.2 4.8 E
133L 121,458–120,427 343 38.9 7.9 ? 3-b hydroxysteroid dehydrogenase
VV A44L (346 aa)/3b-hydroxysteroid dehydrogenase 44%/63% in 343 Moore and Smith (1992)
134R 121,497–121,967 156 18.3 10.0 ? mda-7 or IL-10, SP
Human mda-7 protein precursor (206 aa) 27%/55% in 175 Jiang et al. (1996)
Human IL-10 precursor (178 aa) 23%/53% in 164 Vieira et al. (1991)
135R 122,043–127,748 1901 217.1 8.2 L 8 TMs, SP
MCV MC035R (2133 aa) 32%/53% in 2025 Senkevich et al. (1997)
136R 127,745–128,800 351 41.1 7.6 ? IFN a/b receptor, 1 Ig domain, SP
VV B19R (353 aa)/IFN a/b receptor 26%/45% in 350 Symons et al. (1995)
137R 128,827–129,288 153 17.6 8.1 E 2 TMs
VV C6L (151 aa) 23%/54% in 139 Goebel et al. (1990)
138R 129,314–130,330 338 38 7.1 ? VV A51R (334 aa) 34%/57% in 331 Goebel et al. (1990)
139R 130,405–130,977 190 22.3 7.8 ? VV A52R (190 aa) 31%/59% in 185 Goebel et al. (1990)
140R 131,009–132,721 570 65.2 10.1 ? Kelch-like protein
VV A55R (564 aa) 30%/54% in 562 Goebel et al. (1990)
SPV C4L (530 aa) 30%/53% in 527 Massung et al. (1993)
Kelch protein (689 aa) 24%/48% in 554 Xue and Cooley (1993)
141R 132,748–133,110 120 13.5 10.0 ? Soluble OX-2, 1 Ig domain, SP
Human OX-2 membrane glycoprotein precursor
(274 aa)
25%/50% in 132 McCaughan et al. (1987)
MYX MA56 (218 aa) 41%/46% in 115 Jackson et al. (1999)
Rhesus radinovirus R15 (253 aa) 29%/38% in 120 Searles et al. (1999)
142R 133,144–134,073 309 35.9 9.6 ? Serine/threonine protein kinase
Human serine/threonine protein kinase VRK1
(396 aa)
51%/70% in 306 Nezu et al. (1997)
VV B1R (300 aa)/serine/threonine protein kinase 49%/67% in 292 Howard and Smith (1989)
143R 134,106–134,810 234 27.8 9.5 L DNA-binding protein, ring domain
SFV N1R (234 aa)/DNA-binding protein 45%/64% in 231 Brick et al. (1998)
144R 134,840–135,643 267 30.8 8.6 L CD46, TM, 3 complement control protein domains, SP
Human membrane cofactor protein CD46 (314 aa) 29%/50% in 271 Liszewski et al. (1991)
VV B5R (317 aa)/EEV membrane glycoprotein/host
range protein precursor
28%/49% in 312 Engelstad et al. (1992)
VV WR C21L (263 aa)/complement control protein
precursor
24%/44% in 256 Kotwal and Moss (1988)
145R 135,898–136,869 323 37.6 7.5 ? CC chemokine receptor, G-protein-coupled receptors
signature, 7 TMs
Human CC chemokine receptor type 8 (355 aa) 44%/68% in 325 Tiffany et al. (1997)
SPV K2R (370 aa)/G-protein-coupled receptor 36%/69% in 364 Massung et al. (1993)
CAPV Q2/3L (381 aa)/G-protein-coupled receptor 35%/63% in 319 Cao et al. (1995)
146R 137,018–138,439 473 55 10.3 ? Virulence factor, 6 ankyrin domains
SFV T5 (328 aa)/virulence factor 28%/53% in 326 Mossman et al. (1996)
VV C9L (634 aa)/ankyrin-like protein 27%/36% in 417 Goebel et al. (1990)
147R 138,461–139,936 491 57.8 9.3 L Virulence factor, 5 ankyrin domains
SFV T5 (328 aa)/virulence factor 25%/53% in 324 Mossman et al. (1996)
VV B4R (558 aa)/ankyrin-like protein 23%/50% in 489 Howard et al. (1991)
148R 139,947–141,377 476 55.7 10.5 ? Virulence factor, 6 ankyrin domains
SFV T5 (328 aa)/virulence factor 24%/54% in 324 Mossman et al. (1996)
VV B4R (558 aa)/ankyrin-like protein 23%/50% in 489 Howard et al. (1991)
149R 141,388–142,392 334 38.1 4.9 E SPI-2, serpin domain
MYX putative serpin-like protein (333 aa) 45%/64% in 331 Petit et al. (1996)
CPV IL-1b-converting enzyme (ICE) (caspase 1)
inhibitor (341 aa)
40%/63% in 338 Ray et al. (1992)
VV WR B13R (345 aa)/SPI-2 41%/62% in 341 Smith et al. (1989)
150R 142,430–142,732 100 12.1 10.5 L TM
SPV C2L (92 aa) 41%/69% in 86 Massung et al. (1993)
151R 142,820–143,821 333 38.5 5.5 E VV C10L (330 aa) 27%/49% in 333 Goebel et al. (1990)
Note. TOE, time of expression as predicted as described in text; SP, signal peptide; TM, transmembrane domain; VV, vaccinia virus; CMPV, camelpox
virus; SFV, Shope fibroma virus; SPV, swinepox virus; CAPV, capripox virus; MYX, myxoma virus; MCV, molluscum contagiosum virus; YMTV, yaba
monkey tumor virus; FPV, fowlpox virus.
a ORFs are numbered starting from the left end of the genome and the direction of transcription is indicated by an L or an R. Underlined ORFs are
diploid because they are present within the ITR.
b The number of amino acids of the YLDV protein.
c Molecular mass of each protein calculated by PEPSTATS in the XGCG package.
d Predicted isoelectric points of proteins calculated by PEPSTATS.
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178 LEE, ESSANI, AND SMITHhave ITRs with a lower A1T content (51.0% and 45.0%)
than the whole genome (56.4 and 60.5%, respectively).
The ITRs of FPV are also less A1T rich than the whole
genome (65.4% versus 69.0%) (Afonso et al., 2000). In the
orthopoxviruses (Goebel et al., 1990; Shchelkunov et al.,
995) and MSV (Afonso et al., 1999), the ITRs and whole
enome have a similar A1T content. In contrast, the ITR
f MCV has a higher A1T content (45%) than the whole
enome (36%) (Senkevich et al., 1996).
rrangement of YLDV ORFs
The YLDV genome contains 150 ORFs of $180 nucle-
tides. In addition an ORF of 159 nucleotides (106L) is
ncluded because a very closely related protein is ex-
ressed by VV and has conserved counterparts in sev-
ral other poxviruses (Betakova et al., 2000). ORFs are
umbered from 1 to 151 starting from the left terminus
nd followed by L (left) or R (right) to indicate the direc-
ion of transcription (Fig. 2). ORFs 1L and 151R are within
he ITR and therefore are identical, leaving 150 unique
RFs. The ORFs are tightly packed and with the excep-
ion of the terminal 758 bp there is little noncoding DNA.
here are only three other positions in the virus genome
here a noncoding DNA region exceeds 200 nucleo-
ides: between ORFs 23L and 24L (376 nucleotides), 120L
nd 121L (201 nucleotides), and 144R and 145R (255
ucleotides).
A striking feature of the YLDV genome is that all genes
ocated within 23 kb of either terminus (1L to 27L and
34R to 151R) are transcribed outward toward the
enomic termini, whereas genes located with the central
100 kb of the genome (28R to 133R) are transcribed
rom either DNA strand. This arrangement is similar to
hat reported for other poxviruses (Goebel et al., 1990;
Massung et al., 1994; Senkevich et al., 1996). It was
postulated that the arrangement of genes in this way
minimizes the production of dsRNA that might induce
production of interferon (IFN) or activate IFN-induced,
antiviral, dsRNA-binding proteins such as protein kinase
R (PKR) or 2959-oligoadenylate synthetase (Smith et al.,
1998). The ORFs encode proteins that range from 53
(106L) to 1901 (135R) amino acids in length with a mean
size of 305 amino acids, and 71 are transcribed rightward
and 80 leftward.
Transcriptional regulatory signals
The VV early termination sequence motif (T5NT) (Yuen
and Moss, 1987) and the late transcriptional start site
TAAAT(G) or TAAAAT(G) (Bertholet et al., 1986; Rosel et
l., 1986; Davison and Moss, 1989) were identified near
he end or at the beginning of many YLDV ORFs. An ORF
as considered likely to be expressed early during in-
ection if a T5NT motif was located within the 35 bp
pstream or 50 bp downstream of the stop codon (but
ot elsewhere within the ORF), and the late transcrip-
(
tional start site (TAAAT or TAAAAT) was not found within
he 50 bp upstream of the start codon. Similarly, an ORF
as predicted to be expressed late if it contained the late
tart site (TAAAT or TAAAAT) overlapping the transla-
ional start codon or within the 50 bp upstream of it and
ithout an intervening ATG, and if there was one or more
5NT motifs within the ORF. Intermediate genes were
redicted by the presence of a TAAA initiator sequence
1–12 bp downstream of the core sequence AAANAA
Baldick et al., 1992). By these criteria 14 ORFs were
redicted to be early, 72 ORFs late, 2 ORFs intermediate,
nd 7 ORFs intermediate/late, and 56 ORFs were unas-
igned (Table 1). The prediction of only 14 early ORFs is
ery likely to be an underestimate. In VV approximately
alf the genome is transcribed early during infection
Boone and Moss, 1978) and some genes known to be
xpressed early in VV, e.g., DNA polymerase and thymi-
ine kinase, are not predicted to be expressed early in
LDV (using the above criteria), but are very likely to be
o. The time of expression of each gene awaits experi-
ental determination.
nalysis of YLDV ORFs
YLDV protein sequences were compared with the
WALL protein database and analyzed for sequence
eatures by XEGCG and SMART programs. Table 1 sum-
arizes the position, length, and predicted transcrip-
ional regulation of each YLDV ORF and the size, isoelec-
ric point, amino acid sequence motifs, and similarity
ith other proteins of each predicted YLDV protein. The
reat majority of YLDV proteins (130/151) have counter-
arts in VV with between 24% (148R) and 84% (92L)
mino acid identity. ORFs without counterparts in VV are
ocated near either terminus (2L, 5L, 7L, 14L, 15L, 16L,
8L, and 21L from the left end and 125R, 134R, 135R,
41R, 145R, and 150R from the right end) and some of
hese ORFs encode proteins with similarity to proteins
rom other viruses or cells.
Proteins encoded within the central region of the YLDV
enome show highest amino acid identity with VV coun-
erparts and with comparable proteins in other poxvi-
uses, whereas genes nearer the termini are more vari-
ble (Fig. 3). Figure 3 also shows that there are relatively
ew ORFs within the central region of the YLDV genome
hat do not have a VV counterpart, which is in contrast to
he more variable termini. Many of the proteins encoded
n the central region are enzymes, transcription factors,
r structural proteins that are essential for VV replication
Moss, 1996) (Fig. 2 and Table 1). With few exceptions,
enes in this region are conserved in position, se-
uence, and orientation compared with VV (Fig. 4). A
imilar conservation of this central block of genes has
een noted in other poxviruses such as MCV and SFVSenkevich et al., 1997; Willer et al., 1999), indicating that
his region is likely to represent the minimal block of
ity (%) o
179GENOME SEQUENCE OF YLDVgenes of an ancestral poxvirus to which genus- and
virus-specific genes have been added at either terminus
during evolution.
Despite the considerable similarity with VV in this
region, there are also some interesting differences (Fig.
4). First, YLDV lacks genes related to VV F11L, F14L, O2L,
I4L, D8L, A25L, A26L, and A31L. The VV D8L protein is
located on the surface of intracellular mature virus (IMV)
particles, is nonessential for virus replication, and en-
ables IMV particles to bind to cells via chondroitin sulfate
(Niles and Seto, 1988; Hsiao et al., 1999). Although YLDV
FIG. 3. A comparison of YLDV and VV proteins. The amino acid ident
is present, the YLDV protein has no counterpart in VV.
FIG. 4. Alignment of YLDV and VV ORFs from the central genomic re
of each ORF. Black and gray arrows represent YLDV and VV ORFs, respective
67R is related to VV ORF C7L, which is located in the left region of the genolacks a D8L-like protein, it contains counterparts of the
other VV IMV surface proteins that bind to cells; e.g., the
proteins encoded by ORFs 74L and 117L are counter-
parts of VV H3L (Lin et al., 2000) and A27L (Chung et al.,
1998), respectively. ORFs A25L and A26L in VV-CPN
represent fragments of the gene encoding the A-type
inclusion body protein of CPV and some other poxviruses
and which in VV strain WR encodes a 94-kDa protein.
This gene has been deleted entirely in YLDV and, con-
sistent with this, electron microscopy of YLDV-infected
owl monkey kidney (OMK) cells revealed no A-type in-
f YLDV proteins with their VV counterparts is illustrated. Where no bar
rrows represent the direction of transcription and approximate lengthgion. A
ly. Underlined VV ORFs are absent from the YLDV genome. YLDV ORF
me.
P180 LEE, ESSANI, AND SMITHclusion bodies (data not shown). VV ORF I4L encodes the
large subunit of ribonucleotide reductase, a protein that
is not encoded in MCV and SFV in addition to YLDV
(Senkevich et al., 1997; Willer et al., 1999). This gene is
nonessential for VV replication in cell culture, although a
VV strain lacking this gene shows a modest attenuation
(Child et al., 1990). VV ORF O2L encodes glutaredoxin I,
and a related gene is absent in YLDV, MCV (Senkevich et
al., 1997), MYX (Cameron et al., 1999), and SFV (Willer et
al., 1999). The functions of the other VV genes from the
central region of the genome for which YLDV has no
counterparts (F11L, F14L, and A31R) are unknown.
The central region of the YLDV genome contains a few
genes that are transposed or oriented inversely with
respect to their VV counterparts (Fig. 4). For instance, the
VV gene C7L, encoding a host range protein (Perkus et
al., 1990; Oguiura et al., 1993), is present in the left
variable region of the VV genome, but in YLDV this gene
(67R) is present in the central region immediately to the
right of the thymidine kinase gene and is transcribed in
the opposite direction. The YLDV equivalent of VV E7L is
also transposed from its position in the VV central region
near the right end of the YLDV genome (ORF 129R). In
SFV and MYX, genes related to VV C7L and E7L are
present in the same position as YLDV, consistent with
the closer relationship of YLDV with leporipoxviruses
T
YLDV ORFs Predicted to Encode Proteins Involved in
Fu
Proteins involved in early transcription RNA polymerase subunits
Poly(A) polymerase
mRNA capping enzyme
RNA polymerase accessor
proteins
Early transcription factors
Proteins involved in intermediate
transcription
Intermediate transcription f
Intermediate transcription f
subunits
roteins involved in late transcription Late transcription factor-1
Late transcription factor-4
Late transcription factor-2
Late transcription factor-3
Late elongation factorthan orthopoxviruses (see Phylogeny below). Several
ORFs in the central region are truncated compared totheir VV counterparts and some of these are considered
under appropriate sections below.
Overall, the predicted YLDV proteins show greatest
similarity to proteins from chordopoxviruses and al-
though in some cases there are related proteins in Afri-
can swine fever virus (ASFV) and MSV, in no case was a
YLDV protein more closely related to proteins from these
viruses than a chordopoxvirus protein. No YLDV protein
was found to be related only to a protein from ASFV or
MSV and not from chordopoxviruses.
Transcriptional proteins
Sequence comparisons showed that YLDV and VV
have very similar transcriptional enzymes and associ-
ated factors. These include the eight subunits of RNA
polymerase (35L, 55R, 69R, 71R, 85R, 96R, 116R, and
119R), early (84R and 98L), intermediate (35L, 99R, and
115R), and late (52R, 58R, 76R, 91L, and 92L) transcription
factors, RNA polymerase-associated protein (RAP) 94
(75L), and the heterodimeric capping (79R and 89L) and
polyadenylating (32L and 68R) enzymes (Table 2). Com-
pared with other proteins, these transcriptional enzymes
show very high conservation between VV and YLDV. For
instance, the two largest RNA polymerase subunits 71R
(rpo147) and 115R (rpo132) share more than 80% amino
ription and Their Counterparts in VV, MCV, and MYX
YLDV VV MCV MYX
rpo30 35L E4L MC034L M030L
rpo7 55R G5.5R MC061R M050R
rpo22 69R J4R MC077R M066R
rpo147 71R J6R MC079R M068R
rpo18 85R D7R MC097R M082R
rpo19 96R A5R MC108R M094R
rpo132 116R A24R MC129R M114R
rpo35 119L A29L MC135L M117L
Catalytic subunit 32L E1L MC031L M027L
Regulatory subunit 68R J3R MC076R M065R
Large subunit 79R D1R MC090R M076R
Small subunit 89L D12L MC101L M087L
RAP 94 75L H4L MC085L M072L
RNA/DNA helicase 49R I8R MC050L M044R
Elongation factor 88L D11L MC100L M086L
84R D6R MC095R M081R
98L A7L MC110L M096L
35L E4L MC034L M030L
99R A8R MC111R M097R
115R A23R MC128R M113R
58R G8R MC067R M053R
76R H5R MC086R M073R
91L A1L MC103L M089L
92L A2L MC104L M090L
52R G2R MC058R M047RABLE 2
Transc
nction
y
actor-1
actor-3acid identity with their corresponding VV proteins. Most
of these proteins are of a very similar length in YLDV and
181GENOME SEQUENCE OF YLDVVV, a notable exception being 35L (VV rpo30), which is 60
amino acids shorter in YLDV. In MCV this protein is
longer than the VV counterpart (Senkevich et al., 1997).
YLDV transcription factors are also of a similar length to
their VV counterparts, with the exception of the YLDV 76R
protein, which is 20 amino acids shorter than the VV
protein H5R. Overall, these data indicate that YLDV has a
transcription system very similar to that of VV.
Nucleic acid modifying enzymes
YLDV, like other poxviruses, has enzymes that are
involved in biosynthesis of nucleic acid precursors.
These include thymidine kinase (66R), the small subunit
of ribonucleotide reductase (20L), and dUTPase (17L).
YLDV lacks counterparts of VV thymidylate kinase and
the large subunit of ribonucleotide reductase. The latter
protein is also absent in MCV and SFV (Senkevich et al.,
1997; Willer et al., 1999). The dUTPase gene is nones-
sential for VV replication but minimizes incorporation of
UTP into DNA. YLDV also lacks a DNA ligase that is
found in VV and some other poxviruses, but which is
nonessential for replication.
DNA replication and repair
YLDV encodes proteins related to VV DNA polymerase
(39L), DNA topoisomerase I (77R), DNA polymerase pro-
cessivity factor (113R), an ATP–GTP-binding protein
(83R), and a serine/threonine protein kinase (142R) that
are all essential for VV DNA replication. These proteins
contained appropriate signatures for their respective
protein families. In addition, YLDV has proteins related to
uracil DNA glycosylase (82R) and mutT (86R and 87R).
Uracil DNA glycosylase functions in DNA repair by indi-
rectly causing excision of uracil from DNA, and the mutT
proteins are putative NTP pyrophosphohydrolases in-
volved in preventing DNA damage (Koonin, 1993). An-
other VV protein implicated in repair of damaged DNA,
DNA ligase (Kerr et al., 1991), is absent from YLDV as
noted above.
Proteins of extracellular enveloped virus
TPV and YLDV make two forms of virus particle that
have different buoyant densities in CsCl (Knight et al.,
1989) (data not shown). IMV remains in the cell and has
a density of 1.26 g/ml, whereas extracellular enveloped
virus (EEV) has an extra lipid envelope and a buoyant
density of 1.24 g/ml in CsCl. In VV, EEV is very important
for virus dissemination and mutants unable to make EEV
are attenuated in vivo. Several proteins specific for the
EEV outer envelope are important for the formation or
dissemination of EEV. In YLDV, there are proteins related
to the VV EEV proteins F13L, A33R, and A34R (genes 27L,
122R, and 123R, respectively), but counterparts of A36R
and A56R are absent. Another VV EEV-specific protein
(B5R) is related to complement control proteins. AlthoughYLDV has a protein (144R) related to complement control
proteins (see below), this is more closely related to the
human protein CD46 than to VV B5R. Thus it is uncertain
whether the YLDV protein 144R is a functional counter-
part of the VV B5R protein, and this awaits experimental
determination. The absence of a counterpart of A36R
protein is interesting. This protein was thought originally
to be part of the EEV envelope because it copurified with
EEV in density gradients (Parkinson and Smith, 1994), but
recently immunogold electron microscopy showed that
the protein was present on intracellular enveloped virus
particles but not cell-associated enveloped (CEV) or EEV
particles (van Eijl et al., 2000). Instead, it is located on the
cytosolic face of the plasma membrane beneath CEV
particles. A36R is essential for the formation of virus-
induced actin tails that drive CEV particles away from the
cell and are important for efficient cell-to-cell spread of
virus (Sanderson et al., 1998; Wolffe et al., 1998; Ro¨ttger
et al., 1999). The absence of an A36R-like protein might
explain why the plaques formed by YLDV take such a
long time to develop, similar to VV plaques formed by
mutants unable to make actin tails.
Host range proteins
Several poxvirus host range proteins have been dis-
covered, such as VV K1L and C7L, which are required for
growth in primate and human cells (Perkus et al., 1990).
YLDV has a protein with 37% amino acid identity to VV
C7L (67R), but as noted above, this is present in the
central region of the YLDV genome, whereas in VV it is
near the left end of the genome. YLDV lacks a counter-
part of K1L. Some poxvirus host range proteins contain
ankyrin repeats, including K1L and the CPV 77-kDa host
range protein (Spehner et al., 1988), and there are sev-
eral other poxvirus proteins of unknown function that
contain ankyrin repeats, such as VV M1L and B4R
(Goebel et al., 1990). YLDV also has several proteins with
ankyrin repeats: Protein 8L has 4 ankyrin repeats and
shares 27% amino acid identity with M1L, and 11L has 14
ankyrin repeats and is more similar to VV B4R. At the
right end of the YLDV genome there is a family of related
genes (146R, 147R, and 148R) encoding proteins with 5 or
6 ankyrin repeats. These share 24 to 29% amino acid
identity with one another and so are unlikely to have
arisen by recent gene duplication. More likely, they were
generated by ancient gene duplication, or the genes
were acquired independently from the host. The func-
tions of these proteins are unknown.
There are several other multigene families in YLDV, for
instance, genes 71L and 145R encode chemokine recep-
tor-like proteins, genes 3L and 4L encode proteins re-
lated to each other and to SPV C5L, genes 2L, 128L,
136R, and 141R encode members of the immunoglobulin
superfamily, and genes 19L and 140R encode proteins
with kelch repeats.
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182 LEE, ESSANI, AND SMITHMonoglyceride lipase
Protein 13L is related (37% identity and 60% similarity)
to mouse monoglyceride lipase, which catalyzes the last
step in the hydrolysis of stored triglycerides in the adi-
pocyte (Karlsson et al., 1997). There is a related but
slightly shorter ORF in CPV strain GRI-90 (Shchelkunov et
al., 1998) (Fig. 5), and in VV the gene is disrupted into two
smaller ORFs, K5L and K6L. The amino acid alignment
(Fig. 5) shows that the three residues of the proposed
catalytic triad [S122, in a GXSXG motif (underlined with
dots), D239, and H269 (arrows)] were all conserved in
YLDV 13L, but in CPV D239 is substituted by N. There is
also a zinc finger domain near the N-terminus that is
conserved in all these proteins (underlined). The enzy-
matic activity of this protein and its role in the poxvirus
biology would be interesting to study.
FIG. 5. Amino acid alignment of YLDV ORF 13L with related protein
program. Arrows mark the amino acids of the catalytic triad of monogl
Solid underline marked a putative zinc finger motif. The black and gray s
in at least two of the three sequences. M.G. lipase, monoglyceride lip
T
YLDV Potentia
YLDV protein Putative mechanism
2L Blockage of CTL-induced apoptosis
7L Binding of chemokines
10L Inhibition of apoptosis
12L Inhibition of eIF2a phosphorylation
14L IL-18-binding protein
16L Inhibition of apoptosis
34L Blockage of dsRNA-induced PKR and 29,59-
oligoadenylate synthetase activation
128L Affects calcium influx into cells
133L Synthesizing steroids (3b-HSD)
134R Similar to mda-7/IL-10 protein family
136R IFN-a/b-binding protein
141R Negative signaling of IL-2 and IFN-g produc
144R Complement inhibition
145R Binding of chemokines
149R Inhibition of apoptosisImmunomodulators
Poxviruses express a wide range of proteins that
counteract the host response to infection (for reviews
see McFadden et al., 1995; Smith et al., 1997), and many of
hese are clustered in the terminal regions of the genome.
LDV also encodes several proteins that are likely to mod-
late the host response to infection (Table 3).
Near the left end of the genome, gene 2L encodes a
rotein with amino acid similarity to major histocompat-
bility class I (MHC-I) antigens from several species, but
s most closely related to chicken MHC-I and to a related
rotein from swinepox virus (SPV) (Massung et al., 1993).
lthough the amino acid identity (22%) and similarity
44%) with chicken MHC-I are low, the YLDV protein
ontains a predicted signal sequence and residues char-
cteristic of the immunoglobulin (Ig) domain (Fig. 6) and
nces from cells and other poxviruses generated using the ClustalW
lipase enzymes. Dotted underline marks the conserved motif GXSXG.
regions represent amino acids that are identical or similar, respectively,
nomodulators
Virus or cellular related proteins
Chicken MHC-I
Human 7TM-CCR8, CAPV Q2/3L, SPV K2R
MYX SERP-I
VV K3L, VAR C3L, SFV 008.2L/R
SPV C9L, MCV MC053L and MC054L, human and mouse
IL-18-binding proteins
MYX M11L
VV E3L, VAR E3L, MYX M029L, SFV S029L
Human CD47, VV A38L, SFV S128L, MYX M128L
VV A44L
VV-WR B18R, VAR B17R
Human OX-2, MYX MA58, SFV S141R
Human CD46, VV C21L and B5Rseque
ycerideABLE 3
l Immu
tionHuman 7TM-CCR8, CAPV Q2/3L, SPV K2R
CPV crmA, VV B13R, MYX M151R, SFV S151R
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183GENOME SEQUENCE OF YLDVhas the domain structure typical of MHC-I. In both YLDV
and SPV the Ig domain is larger than the cellular coun-
terparts (Fig. 6). Unlike the membrane-bound MHC-I an-
tigens of cells and other viruses, such as human cyto-
megalovirus (Browne et al., 1990) and MCV (Senkevich
nd Moss, 1998), the YLDV protein lacks a C-terminal
ydrophobic membrane anchor and so might be se-
reted. The 2L ORF spans the junction of the left ITR and
erminates 21 nucleotides into the ITR. ITRs may in-
rease or decrease in length as a result of transpositions
f DNA from one end of the genome to another (Moyer et
l., 1980) and so such a transposition may have trun-
ated the 2L ORF and removed the C-terminal membrane
nchor and cytoplasmic tail. Whatever its derivation, the
resent protein is likely to be secreted and might bind b2
microglobulin and short peptides. Possibly this complex
might bind to T cells and thereby prevent lysis of virus-
infected cells.
The proteins encoded by genes 7L and 145R are
related to each other (44.6% identity and 59.4% similarity)
and to the family of chemokine receptors. These hydro-
phobic proteins have a hydrophilic N-terminus, 7 trans-
membrane domains, and a short cytoplasmic domain.
ORF 7L has 53% identity and 73% similarity with human
CC chemokine receptor 8 (Tiffany et al., 1997) and slightly
higher similarity with the corresponding protein from
Macaca mulatta (Margulies et al., 1999). ORF 145R has
44% identity and 68% similarity with the same human
protein. Genes encoding chemokine receptor-like pro-
teins have been described in SPV and capripox virus
(Massung et al., 1993; Cao et al., 1995) but the proteins
have not been characterized. Compared to other poxvi-
FIG. 6. Amino acid alignment of YLDV protein 2L with SPV C1L and
the ClustalW program. Solid underline marks the Ig domain, and the box
proteins. The black and gray shaded regions represent amino acids tharus immunomodulators, the degree of relatedness of
YLDV ORFs 7L and 145R with cellular counterparts ishigh. This suggests that these proteins may bind che-
mokines and modulate the immune response to infec-
tion.
YLDV encodes two proteins with similarity to serine
protease inhibitors (serpins) and related proteins have
been described in the other poxviruses (for review see
Turner et al., 1995). Protein 10L is most closely related to
the secreted serpin encoded by MYX (MYX SERP-I) and
which has been shown to inhibit the activity of several
serine proteases (Nash et al., 1998). Protein 149R has
38% amino acid identity with CPV crmA (VV B13R). This
protein is an intracellular inhibitor of caspase 1 (Ray et
al., 1992; Kettle et al., 1997), which has roles in apoptosis
and in the processing of pro-interleukin (IL)-1 and pro-
IL-18 into IL-1 and IL-18, respectively. A similar role is
predicted for the YLDV protein.
Gene 15L encodes a putative growth factor with 40%
amino acid identity with MYX growth factor. The YLDV
protein has a signal peptide and the epidermal growth
factor signature (CLCKRQFNGKRC) and is likely to func-
tion in a manner similar to that of other poxvirus growth
factors.
YLDV encodes several proteins predicted to interfere
with IFN. Proteins 12L and 34L are related to VV proteins
K3L and E3L, which prevent the antiviral activity of IFN-
induced proteins PKR and 29,59-ologoadenylate syn-
thetase within infected cells (for review see Smith et al.,
1998). In addition, YLDV protein 136R shares 28% amino
acid identity with VV B18R (strain WR) and B19R (strain
CPN) proteins that function as a soluble and cell surface
type I IFN-binding protein (Colamonici et al., 1995; Sy-
mons et al., 1995; Alcamı´ et al., 2000). Like the VV protein,
MHC-I sequences from chicken (C) and mouse (M) generated using
dues represent the transmembrane anchor sequence of cellular MHC-I
entical or similar, respectively, in at least three of the four sequences.relatedthe YLDV protein has a signal peptide followed by three
Ig domains. YLDV lacks a protein with similarity to the
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184 LEE, ESSANI, AND SMITHsoluble IFN-g-binding protein made by VV and many
ther poxviruses. Finally, YLDV protein 14L has similarity
o IL-18-binding proteins from humans, mice, and poxvi-
uses (Novick et al., 1999; Xiang and Moss, 1999a, b;
Born et al., 2000; Smith et al., 2000) (Fig. 7). Each protein
has a signal peptide (underlined) and several potential
sites for attachment of N-linked glycans (boxed). IL-18,
also known as IFN-g-inducing factor, is a potent cytokine
hose activities include the induction of IFN and the
h1-type immune response.
YLDV protein 144R has 30% amino acid identity with
uman CD46 (membrane cofactor protein). CD46 is a
PI-anchored protein that regulates complement activity
n the cell surface, has four short consensus repeat
SCR) domains typical of complement regulatory pro-
eins, and is also a cellular receptor for measles virus.
he YLDV protein 144R has a signal peptide followed by
n extracellular domain containing three SCR domains.
t the C-terminus there is a hydrophobic transmembrane
omain, such that the protein might be retained on the
ell surface as a glycoprotein with type I membrane
opology. Gene 144R encodes the only YLDV protein
elated to complement control proteins, whereas VV has
wo proteins: C21L and B5R. C21L is a secreted protein
alled vaccinia complement protein, which binds C3b
nd C4b and prevents activation of the complement
ascade (Kotwal and Moss, 1988; Kotwal et al., 1990).
owever, B5R forms part of the outer envelope of EEV
nd has not been shown to possess anti-complement
ctivity (Engelstad et al., 1992; Isaacs et al., 1992). Al-
hough VV does not express a protein with CD46-like
roperties, during VV morphogenesis CD46 and other
ost complement regulatory proteins such as CD55 and
D59 are incorporated onto the EEV outer envelope
Vanderplasschen et al., 1998). CD55 in particular con-
ributes to the resistance of EEV to destruction by com-
FIG. 7. Amino acid alignment of YLDV protein 14L with mouse and h
trains Hampstead and Naval, MCV MC053L and MCV054L, and SPV C
ray shaded regions represent amino acids that are identical or sim
epresent hydrophobic signal peptides and boxes indicate potential alement.
YLDV protein 133L has 44% amino acid identity with VV44L, a 3b-hydroxysteroid dehydrogenase (3b-HSD) en-
zyme. In cells this enzyme is essential for the synthesis
of all classes of steroid hormones, mineralocorticoids,
glucocorticoids, and sex hormones. The VV protein is
active and contributes to virus virulence (Moore and
Smith, 1992). Potentially, the YLDV protein may function
in a similar way.
YLDV protein 134R has similarity to melanoma differ-
entiation antigen (mda)-7 (Jiang et al., 1996) and mem-
bers of the IL-10 family (Vieira et al., 1991). The protein
contains a signal peptide and a hydrophilic extracellular
domain, but lacks an anchor sequence and so is likely to
be secreted. Some other viruses such as Epstein–Barr
virus and OV encode IL-10-like proteins; however, these
proteins are very closely related to the IL-10 proteins of
their host (human and sheep, respectively), with over
80% amino acid identity in each case (Hsu et al., 1990;
Fleming et al., 1997). In contrast, the YLDV protein has
only 23% identity and 53% similarity with human IL-10.
Recently, an IL-10-like protein was discovered in herpes
virus simairi (K55), which shares 25% amino acid identity
with IL-10 (Knappe et al., 2000), and other members of
this family are being identified. Therefore, YLDV 134R
may represent a virus version of another member of this
family. Melanoma differentiation antigen-7 has anti-pro-
liferative properties for cancer cells (Jiang et al., 1995,
1996). The potential role of mda-7 in YLDV biology is not
clear.
YLDV protein 141R has 33% amino acid identity with
the human T cell costimulatory protein OX-2 (Mc-
Caughan et al., 1987) and to related proteins in SFV and
MYX (Cameron et al., 1999; Willer et al., 1999). Some
herpes viruses also contain OX-2-related proteins (Russo
et al., 1996). OX-2 is a membrane-bound protein on the
surface of dendritic cells and has two Ig domains
(Gorczynski et al., 1999; Ragheb et al., 1999). In contrast,
IL-18-binding proteins and related proteins from ectromelia virus (EV)
alignment was generated using the ClustalW program. The black and
pectively, in at least six of the eight sequences. Underlined regions
nt sites for N-linked glycans.uman
9L. Thethe sequence of YLDV 141R predicts a soluble protein
with only a single Ig domain (Fig. 8). Potentially, this
k185GENOME SEQUENCE OF YLDVYLDV protein might affect the function of T-cells in
mounting an antiviral response.
Immunomodulators from other poxviruses that are ab-
sent from YLDV include soluble proteins that bind tumor
necrosis factor, IL-1b, or CC chemokines.
Finally, TPV was reported to encode a secreted, 38-
Da protein that bound IL-2, IL-5, and IFN-g (Essani et al.,
1994). The sequence of the YLDV genome provides no
obvious candidate for such a protein. While it is possible
that YLDV and TPV differ in the expression of this protein,
the sequence of 12.5 and 10.7 kb from the left and right
ends, respectively, of the TPV genome showed that YLDV
and TPV are very closely related (.98.6% nucleotide
identity) and the predicted proteins were extremely sim-
ilar (data not shown).
YLDV-specific proteins
Seven YLDV genes (22L, 23L, 28R, 126R, 130L, 131R,
and 132R) encoded proteins with no significant similarity
to other proteins in databases. These are located toward
the genomic termini and show clustering, suggesting
that some of these might have been acquired simulta-
neously. Protein 28R is predicted to encode a protein
with one transmembrane domain. Protein 126R has a
putative signal peptide, and protein 130L encodes a
putative 21.2-kDa secreted protein. Both 126R and 130L
are likely to be glycosylated.
Phylogeny
Comparison of YLDV proteins with proteins from other
poxviruses indicates that YLDV is very closely related to
YMTV (where sequence availability permits comparison).
Outside the yatapoxvirus genus, YLDV is most closely
related to SPV and leporipoxviruses than to orthopoxvi-
FIG. 8. Schematic representation of the YLDV protein 141R and
human OX-2, rhesus radinovirus (RRV) R15 and MYX MA56. Positions of
cysteines (S), forming intramolecular disulfide bonds, and predicted
sites for attachment of N-glycans are marked. NH2, amino terminus;
COOH, carboxyl terminus. Circles represent Ig domains of the variable
(V) or constant 2 (C2) types.ruses, FPV and MCV. Unrooted phylogenic trees were
constructed for several proteins, including a protein fromthe central region of the genome with a role in transcrip-
tion (VV D12L), an IMV protein (D13L), an EEV-specific
protein (VV F13L), and an immunomodulator (VV E3L)
(Fig. 9). In cases where a SPV protein is available for
comparison, the YLDV protein is most closely related to
SPV. In addition, in the left end of the genome, which has
been sequenced in SPV (Massung et al., 1993), the YLDV
proteins show a consistently higher amino acid identity
and similarity to SPV proteins than to proteins from other
poxviruses (Table 1). Excluding other yatapoxviruses,
YLDV proteins are most closely related to leporipoxvirus
proteins where SPV sequence data were not available.
Conclusion
The genome sequence of YLDV, a yatapoxvirus, has
been determined. The genome is the smallest poxvirus
that has been sequenced hitherto and contains 151
ORFs. Comparisons with other poxviruses show that
YLDV has very similar transcriptional and DNA replica-
tive enzymes and many structural proteins for both IMV
and EEV particles. YLDV contains some potential immu-
nomodulators found in other poxviruses and others not
reported elsewhere. Phylogenic analysis shows that
YLDV is more closely related to SPV and leporipoxvi-
ruses than to orthopox, molluscipox, and avipox viruses.
MATERIALS AND METHODS
Cells and viruses
OMK cells were grown in minimum essential medium
(MEM) containing 5% fetal bovine serum (FBS). A virus
sample labeled simian poxvirus (tanapox virus Davies
strain) was obtained from the American Type Culture
Collection but after growth, purification, and restriction
analysis of the virus genome, this virus was found to be
distinct from TPV and indistinguishable from YLDV
(Knight et al., 1989). TPV was then obtained from Joe
Esposito (Center for Disease Control, Atlanta, GA).
Stocks of each virus were grown in OMK cells for 5 days.
Virus present in the infected cells was released by three
cycles of freeze/thawing and sonication and the infectiv-
ity was determined by plaque assay on OMK cells for 11
days under a semisolid overlay [MEM containing 1.5%
(w/v) carboxymethyl cellulose, 2.5% FBS]. After removal
of the overlay, cell monolayers were stained with 0.1%
(w/v) crystal violet in 15% ethanol.
YLDV was purified from cytoplasmic extracts of in-
fected cells by sucrose density gradient centrifugation as
described for VV (Mackett et al., 1985). Briefly, infected
cells were swollen in hypotonic buffer and dounce-ho-
mogenized, and the nuclei were removed by centrifuga-
tion. The postnuclear supernatant was sonicated and
virus was sedimented through a 36% (w/v) sucrose cush-
ion. This virus pellet was resuspended by sonication and
trypsinized, and virions were purified by two cycles of
tabase
lly CON
186 LEE, ESSANI, AND SMITHcentrifugation in 15–40% (w/v) sucrose density gradients.
Virus was stored in 1 mM Tris–HCl (pH 9). Virus DNA
was extracted from purified virus as described (Esposito
et al., 1981).
Construction of sequencing library and DNA
sequencing
Virus DNA was broken randomly by sonication, and
DNA fragments were made blunt-ended by treatment
with S1 nuclease (Gibco BRL) and resolved by agarose
gel electrophoresis. Fragments of 0.8 to 2 kb were re-
covered by electroelution and ligated into SmaI-digested
pUC118 DNA that had been treated with calf intestinal
alkaline phosphatase to remove 59-phosphate groups. To
FIG. 9. Unrooted phylogenic trees of four YLDV proteins and related
D12L). (B) IMV protein (VV D13L). (C) EEV-specific protein (VV F13L).
follows: Protein sequences were retrieved from the SWALL protein da
NEIGHBOR (which generated 100 different phylogenic trees), and finaobtain larger DNA fragments for primer walking, virus
DNA was digested partially with Sau3AI and fragmentsof approximately 10 kb were ligated into BamHI-digested
pUC118. Each library of ligated fragments was trans-
formed into Escherichia coli TG1 cells and bacterial
clones were selected on agar plates containing ampicil-
lin. In some cases, bacteriophage m13K07 was used to
infect pUC118-transformed TG1 cells to make single-
stranded (ss)DNA as described by the manufacturer
(New England Biolabs). DNA (ss or ds) for sequencing
reactions was prepared by a Qiagen BioRobot 9600.
Clones were sequenced using the dideoxy chain ter-
mination method of Sanger et al. (1977) on an ABI 373
automated DNA sequencer using cycle sequencing and
dye terminators (ABI Prism BigDye Termination Cycle
Sequencing Ready Reaction Kit with AmpliTaq DNA Poly-
s from other poxviruses. (A) mRNA capping enzyme small subunit (VV
NA-binding protein (VV E3L). The consensus tree was generated as
and aligned by CLUSTAL W. Data were processed by PRODIST and
SENSUS was used to draw the consensus trees. OV, orf virus.protein
(D) dsRmerase). Random DNA sequence was processed with
the Staden computer program package (Bonfield et al.,
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187GENOME SEQUENCE OF YLDV1995). The program PREGAP was used to convert data
into a format suitable for assembly, to identify vector
sequence, and to eliminate poor-quality data. Base call-
ing and quality checks were performed manually using
TREV and contaminating host sequences were identified
and eliminated using REPE. Assembly was achieved
with GAP4. During the final stages of assembly, gaps
were filled by sequencing directly from whole virus DNA
using oligonucleotide primers.
Determination of the DNA sequence composition and
identification of ORFs were achieved using the program
XNIP (Bonfield et al., 1995). Sequence similarity searches
ith the protein database SWALL (European Bioinformat-
cs Institute, EBI, http://www.ebi.ac.uk) were performed
ith WU-BLASP (Altschul et al., 1990; Altschul and Gish,
996). Programs XEGCG (Program manual for the Wis-
onsin Package, Version 8, Genetics Computer Group,
adison, WI) and SMART version 2.0 (Schultz et al.,
998) were used for detailed analysis of each protein.
rograms ClustalW (Thompson et al., 1994) and Genedoc
version 2.0) (http://www.cris.com/;ketchup/genedoc.
html) were used to manipulate the multiple sequence
ile. TreeView (Page, 1996) was used for phylogenetic
nalysis.
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